Central Nervous System Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Central Nervous System Treatment Market
The central nervous system treatment market size was valued at USD 81.67 billion in 2020, and the market is now projected to grow from USD 89.02 billion in 2021 to USD 166.53 billion by 2028, exhibiting a CAGR of 9.4% during the forecast period of 2021-2028.
Pandemic disrupted delivery chain of CNS therapeutics, brought about a drop in earnings of about USD 1.4 billion in 2020. Pharmaceutical corporations have shifted their research and Development expenditure and personnel closer. Over-the-counter products, like anesthesia, moreover skilled a dip in revenue boom because of decrease demand. However, the marketplace is predicted to stabilize and display surprising growth in 2021, reverting to pre-pandemic levels.
New neurological disease remedies are expected to pressure central nervous system treatment market growth, in particular in growing international locations. Corbus Pharmaceuticals Inc.'s Lenabasum, presently in Phase 3 scientific trial, is prepared to release globally through using 2023.
One of the huge traits that the market well-known shows are mergers, acquisitions, and partnerships. Predominant companies within the market concerned in innovating principal apprehensive gadget treatment capsules have entered into distribution and developmental agreements with fellow competition. For instance, in February 2020, Biogen agreed with Sangamo Therapeutics to innovate gene remedy pills for diverse neurological diseases. Such strategic steps taken by means of key groups working inside the CNS therapeutics marketplace will notably enhance the prospects of the industry.
Comprehensive Analysis of Central Nervous System Treatment Market
The market is classified into neurovascular diseases, neurodegenerative sicknesses, highbrow fitness, and infectious ailments. Neurodegenerative ailments, collectively with multiple sclerosis and Alzheimer's ailment, dominated the market due to accelerated sales and R&D investments. Mental fitness issues also are increasing due to strain, tension, and dangerous diets, with the COVID-19 pandemic inflicting an upward thrust in call for antidepressants and analgesics. The drug magnificence phase consists of immunomodulators, interferons, decarboxylase inhibitors, dopamine agonists, antidepressants, analgesics, and other imperative frightened remedy pills. Immunomodulators dominate the marketplace in 2020 because of consistent innovation and development of therapeutic molecules. The non-biologics phase, with Biogen's Tecfidera having the very best sales, is driven by using the growing incidence of neurological diseases, strong government guide, and favourable fitness reimbursement. The distribution channel section is split into health centre pharmacies and retail pharmacies, with online pharmacies projected to witness a lucrative CAGR because of internet penetration in emerging countries.
The North America region lead the central nervous system treatment market share by benefitting a market size of USD 38.25 billion in 2020 due to the presence of key players and higher access to CNS disorder treatment. Government agencies like the U.S. FDA are actively informing the public and healthcare professionals about treatment and regulatory guidelines for managing CNS diseases.
The market for critical worried gadget therapeutics is fragmented because of the presence of various organizations. Biogen dominates the market, with its crucial molecules generating great sales in 2020. Other players embody Johnson and Johnson Services, Pfizer, Biogen, Pfizer, Hoffman-La Roche, Novartis, Teva Pharmaceutical Industries and Otsuka Holdings.
Johnson and Johnson has obtained FDA popularity of the each day oral drug Ponvory, that is supposed for treating more than one sclerosis.
Segmentation Table
ATTRIBUTE
DETAILS
Study Period
2017-2028
Base Year
2020
Estimated Year
2021
Forecast Period
2021-2028
Historical Period
2017-2019
Unit
Value (USD billion)
Segmentation
Disease Type, Drug Class, Drug Type, Distribution Channel, and Region
By Disease Type
Neurovascular Diseases
- Hemorrhagic Stroke
- Ischemic Stroke
- Others
Neurodegenerative Diseases
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Others
Mental Health
- Epilepsy
- Mood Disorders
- Anxiety Disorders
- Others
Infectious Diseases
- Meningitis
- Encephalitis
- Others
Others
By Drug Class
Immunomodulatory Drugs
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Antidepressants
Analgesics
Others
By Drug Type
Biologics
Non-biologics
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America (By Disease Type, By Drug Class, By Drug Type By Distribution Channel, and By Country)
- U.S. (By Drug Type)
- Canada (By Drug Type)
Europe (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and By Country)
- U.K. (By Drug Type)
- Germany (By Drug Type)
- France (By Drug Type)
- Italy (By Drug Type)
- Spain (By Drug Type)
- Rest of Europe (By Drug Type)
Asia Pacific (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and By Country)
- China (By Drug Type)
- Japan (By Drug Type)
- India (By Drug Type)
- Australia (By Drug Type)
- Southeast Asia (By Drug Type)
- Rest of Asia Pacific (By Drug Type)
Latin America (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and by Country)
- Brazil (By Drug Type)
- Mexico (By Drug Type)
- Rest of Latin America (By Drug Type)
Middle East & Africa (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and by Country)
- GCC (By Drug Type)
- South Africa (By Drug Type)
- Rest of Middle East & Africa (By Drug Type)
Please Note: It will take 5-6 business days to complete the report upon order confirmation.